Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS
Trial details
- Registry ID
- NCT04957485
- Phase
- Phase 2
The FDA approved Tecovirimat (TPOXX) on 13 Jul 2018.
Drug identity checked against registry records
Also recorded as TPOXX
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOSNCT04957485 | SIGA Technologies | Phase 2 | Active not recruiting | 2027-01-01Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2018-07-13Day | Tecovirimat | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA208627", "applicant_as_listed_by_fda": "SIGA TECHNOLOGIES", "brand_names": ["TPOXX"], "active_ingredients": ["TECOVIRIMAT"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20180713", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |